TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16220454

Group type: EXPERIMENTAL
Intervention: Preoperative radiochemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative and postoperative radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative and postoperative chemotherapy
Number of subjects: 0
Study: 12149204

Group type: EXPERIMENTAL
Intervention: Low-dose Methotrexate (LDMTX: 6 oral doses of 30 mg/m(2)) plus intravenous Mercaptopurine (MP: 1 g/m(2))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose Methotrexate (HDMTX: intravenous 1 g/m(2)) plus intravenous Mercaptopurine (MP: 1 g/m(2))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mercaptopurine (MP: 1 g/m(2)) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate plus Mercaptopurine (MTX + MP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose Methotrexate plus Mercaptopurine (HDMTX + MP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose Methotrexate plus Mercaptopurine (LDMTX + MP)
Number of subjects: 0
Study: 10103141

Group type: COMPARATOR
Intervention: cBZr parameters measured using PET (Bmax, Kd, B/F ratios)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Anxiety scores from Spielberger's and Covi's scales
Number of subjects: 20
Study: 8540791

Group type: EXPERIMENTAL
Intervention: Hypermobile group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 20
Study: 2189839

Group type: EXPERIMENTAL
Intervention: Physiotherapy instruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no physiotherapy instruction)
Number of subjects: 60
Study: 7361026

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Ibuprofen (IPF)
Number of subjects: 134
Study: 30617584

Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allografts (FDBAs)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (BCP) bone substitute
Number of subjects: 13
Study: 28264922

Group type: EXPERIMENTAL
Intervention: RDN (Renal Denervation)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 139
Study: 25588785

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 23771541

Group type: EXPERIMENTAL
Intervention: Adrenaline (1/200,000, 5 ml) during nasal packing (Group A1)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Adrenaline (1/200,000, 5 ml) during nasal packing with desflurane (Group A2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Desflurane administration (Group C)
Number of subjects: 62
Study: 21358314

Group type: EXPERIMENTAL
Intervention: gemfibrozil, niacin and cholestyramine therapy
Number of subjects: 143

Group type: COMPARATOR
Intervention: lifestyle intervention and placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: lifestyle intervention and pharmacologic therapy
Number of subjects: 143
Study: 19587364

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater insulin secretion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower baseline fasting glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower baseline 2-h glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS) and metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male sex and insulin sensitivity
Number of subjects: 0
Study: 17768286

Group type: EXPERIMENTAL
Intervention: 5-2-1 Go! intervention (Planet Health obesity prevention curriculum plus School Health Index for Physical Activity and Healthy Eating) implemented during 2 school years (November 2002 - May 2004)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 749
Study: 17160917

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (decreased caloric intake and increased physical activity)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Standard diabetes support and education
Number of subjects: 5145
Study: 14573726

Group type: EXPERIMENTAL
Intervention: 200 ppb sulphur dioxide (SO2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 microg/m3 and 2000 microg/m3 aerosols of ammonium bisulphate (AB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air exposure (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal lavage fluid ascorbic acid (AA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal lavage fluid uric acid (UA)
Number of subjects: 0
Study: 10582932

Group type: EXPERIMENTAL
Intervention: Hospital at home
Number of subjects: 229

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Hospital at home (admitted patients)
Number of subjects: 229
Study: 8934214

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 mg bid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nitrendipine (5 mg bid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Enalapril, Nitrendipine, Placebo
Number of subjects: 18
Study: 1877056

Group type: EXPERIMENTAL
Intervention: Bubble oxygenator without an arterial line filter (Group I)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bubble oxygenator with a depth adsorption filter (Group II)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Membrane oxygenator without a filter (Group III)
Number of subjects: 66
Study: 6416701

Group type: EXPERIMENTAL
Intervention: 30 mg/30 ml Adriamycin
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: 20 mg/40 ml Adriamycin
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: 20 mg/40 ml mitomycin C
Number of subjects: 575

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 575
Study: 31230933

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 0
Study: 27379829

Group type: EXPERIMENTAL
Intervention: Daily combination of vitamin D3 (1200 IU), folic acid (0.5 mg), vitamin B12 (0.5 mg), vitamin B6 (50 mg), and calcium carbonate (456 mg) (group A)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Vitamin D3 and calcium carbonate alone (group B)
Number of subjects: 65
Study: 24629690

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet plus moderate aerobic exercise (HDE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HDE plus antioxidants (HDEA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal weight subjects (control group)
Number of subjects: 30
Study: 23153006

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (GIS) applied to permanent molars
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fluoride varnish (FV) applied to permanent molars
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both GIS and FV
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GIS
Number of subjects: 80
Study: 22217987

Group type: COMPARATOR
Intervention: Itraconazole 200 mg orally daily for 4 days, then 200 mg once weekly for 6 months
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: K-712, 1 tablet twice a day for 4 weeks and then for the first 2 weeks of each month for a total of 6 months
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: K-712
Number of subjects: 82

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 82
Study: 19727232

Group type: EXPERIMENTAL
Intervention: Auditory integrative training (AIT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 81
Study: 17323595

Group type: EXPERIMENTAL
Intervention: Sildenafil (phosphodiesterase type 5 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study: 15206088

Group type: EXPERIMENTAL
Intervention: Ointment-based product
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aerosol spray
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 11148806

Group type: EXPERIMENTAL
Intervention: Low-dose sequential HRT
Number of subjects: 82

Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 82
Study: 9102063

Group type: EXPERIMENTAL
Intervention: MFP-SR (76 mg b.i.d.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8406965

Group type: EXPERIMENTAL
Intervention: alpha‐phase gutta‐percha delivered with a plastic core‐carrier, Thermafil
Number of subjects: 51

Group type: COMPARATOR
Intervention: standard beta‐phase gutta‐percha with lateral condensation
Number of subjects: 51
Study: 3517388

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BC)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (CC)
Number of subjects: 140
Study: 30201101

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (10-year duration)
Number of subjects: 3802

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3802
Study: 26650434

Group type: EXPERIMENTAL
Intervention: High-protein diet (2.2 g protein/kg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard-protein diet (1.1 g protein/kg/day)
Number of subjects: 100
Study: 25899445

Group type: EXPERIMENTAL
Intervention: 3 mg weekly dose of sirolimus (SIR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo equivalent
Number of subjects: 34
Study: 23537892

Group type: EXPERIMENTAL
Intervention: Intravenous B-type natriuretic peptide (BNP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 16
Study: 21911349

Group type: EXPERIMENTAL
Intervention: Fast-paced television cartoon
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational cartoon
Number of subjects: 60

Group type: COMPARATOR
Intervention: Drawing for 9 minutes
Number of subjects: 60
Study: 18926433

Group type: EXPERIMENTAL
Intervention: Rolofylline 10 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Rolofylline 20 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Rolofylline 30 mg
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 16283422

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041
Study: 12690275

Group type: EXPERIMENTAL
Intervention: GenHevac B vaccine (3 standard injections at 30-day intervals)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no medication or vaccination)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: GenHevac B vaccine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study: 12579420

Group type: EXPERIMENTAL
Intervention: Tidal volume of 5 ml/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tidal volume of 10 ml/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tidal volume of 15 ml/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tidal volume of 5 ml/kg after volume resuscitation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tidal volume of 10 ml/kg after volume resuscitation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tidal volume of 15 ml/kg after volume resuscitation
Number of subjects: 20
Study: 10573247

Group type: EXPERIMENTAL
Intervention: Habitual snoring
Number of subjects: 1186
Study: 8735575

Group type: EXPERIMENTAL
Intervention: Social feedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: Computer feedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 60
Study: 1820897

Group type: EXPERIMENTAL
Intervention: 5‐ASA capsule formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulphasalazine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single unit tablet of 5‐ASA
Number of subjects: 0
Study: 6349765

Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin (BCG) maintenance therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cyclophosphamide (orally administered)
Number of subjects: 44
Study: 26951205

Group type: EXPERIMENTAL
Intervention: Phenolic-rich olive leaf extract (OLE) 136 mg oleuropein; 6 mg hydroxytyrosol
Number of subjects: 60
Study: 26774673

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) supplementation (2 × 500 mg/day for four months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24838678

Group type: EXPERIMENTAL
Intervention: B2 regimen (two meals a day: breakfast and lunch)
Number of subjects: 54

Group type: COMPARATOR
Intervention: A6 regimen (six smaller meals)
Number of subjects: 54
Study: 22784030

Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise (walking and cycling, 30-45 min, 3-5 days·week⁻¹)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study: 20812996

Group type: EXPERIMENTAL
Intervention: Rehabilitative ultrasound imaging (RUSI)
Number of subjects: 16
Study: 17653942

Group type: EXPERIMENTAL
Intervention: High intensity rehabilitation (4-hour/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control rehabilitation (2-hour/day)
Number of subjects: 68
Study: 15786549

Group type: EXPERIMENTAL
Intervention: 3-day rabeprazole-based triple therapy (amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., rabeprazole 20 mg b.i.d.)
Number of subjects: 115

Group type: COMPARATOR
Intervention: 7-day rabeprazole-based triple therapy (amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., rabeprazole 20 mg b.i.d.)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 3-day rabeprazole-based triple therapy
Number of subjects: 115

Group type: COMPARATOR
Intervention: 7-day rabeprazole-based triple therapy
Number of subjects: 115
Study: 11932292

Group type: EXPERIMENTAL
Intervention: fenproporex 25 mg/d
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: sibutramine 10 mg/d
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: orlistat 120 mg tid
Number of subjects: 31
Study: 9428449

Group type: EXPERIMENTAL
Intervention: Bicarbonate bath of 40 mEq/L (experimental group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard bicarbonate bath of 35 mEq/L (control group)
Number of subjects: 36
Study: 8085374

Group type: EXPERIMENTAL
Intervention: SPf(66)n, a chimeric molecule derived from Plasmodium falciparum proteins, details on dosage and duration not available
Number of subjects: 0
Study: 2547325

Group type: EXPERIMENTAL
Intervention: Fentanyl-N2O/O2 (60:40)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane (adults, 0.9%; children, 1.2%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Halothane (adults, 0.6%; children, 0.7%)
Number of subjects: 60
Study: 1008247

Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia (NLA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modification of infusion regimen (substituting glucose solution with distilled water and Ringer lactate with normal saline and 5 mval/l KCI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Infused sodium and water
Number of subjects: 60
Study: 30484833

Group type: EXPERIMENTAL
Intervention: Any oral anticoagulant
Number of subjects: 12417

Group type: EXPERIMENTAL
Intervention: Direct-acting oral anticoagulants (DOACs)
Number of subjects: 12417

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 12417

Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 12417

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 12417
Study: 26817808

Group type: EXPERIMENTAL
Intervention: Citalopram and general discussions (Group B)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy and general discussions (Group C)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Rehabilitation alone (Group A)
Number of subjects: 274
Study: 26116494

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24064776

Group type: EXPERIMENTAL
Intervention: Promotor pesticide safety training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard video‐based training
Number of subjects: 0
Study: 20194455

Group type: EXPERIMENTAL
Intervention: Nonbiologic DMARD treatment after 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low response to treatment at 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High clinical disease activity thereafter
Number of subjects: 0
Study: 18955912

Group type: EXPERIMENTAL
Intervention: No physical protection
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: C-collar
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Manual in-line immobilization
Number of subjects: 26

Group type: COMPARATOR
Intervention: All techniques (No physical protection, C-collar, Manual in-line immobilization)
Number of subjects: 26
Study: 16869005

Group type: EXPERIMENTAL
Intervention: Occupational health interventions (OHI)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Randomized controlled trial
Number of subjects: 148

Group type: COMPARATOR
Intervention: Controlled trial
Number of subjects: 148

Group type: COMPARATOR
Intervention: Interrupted time-series
Number of subjects: 148

Group type: COMPARATOR
Intervention: Different design
Number of subjects: 148
Study: 14668283

Group type: EXPERIMENTAL
Intervention: Folic Acid (FA; 400 microg)
Number of subjects: 4926

Group type: EXPERIMENTAL
Intervention: Folic Acid + Iron (60 mg)
Number of subjects: 4926

Group type: EXPERIMENTAL
Intervention: Folic Acid + Iron + Zinc (30 mg)
Number of subjects: 4926

Group type: EXPERIMENTAL
Intervention: Multiple Micronutrients (MNs)
Number of subjects: 4926

Group type: COMPARATOR
Intervention: Control (Vitamin A only)
Number of subjects: 4926
Study: 11289091

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with morphine and ketorolac
Number of subjects: 22

Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 22
Study: 9428033

Group type: EXPERIMENTAL
Intervention: Nucleus Mini 22 Cochlear Implant System with SPEAK coding strategy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Clarion Cochlear Implant System with CIS coding strategy (and one with CA coding strategy)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nucleus Mini 22 Cochlear Implant System
Number of subjects: 168

Group type: COMPARATOR
Intervention: Clarion Cochlear Implant System
Number of subjects: 168
Study: 10133873

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition
Number of subjects: 51

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 51
Study: 3329207

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 41
Study: 2516090

Group type: EXPERIMENTAL
Intervention: Carbohydrate-based diet (53% carbohydrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat-based diet (55% fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5% dextrose administration (D5W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 weeks of feeding (general)
Number of subjects: 0
Study: 31793386

Group type: EXPERIMENTAL
Intervention: Education about andropause health
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 30701617

Group type: EXPERIMENTAL
Intervention: Continuous moderate‐intensity exercise + prior carbohydrate intake (10 g per person)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intermittent high‐intensity exercise + prior carbohydrate intake
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous moderate‐intensity exercise
Number of subjects: 8
Study: 28291781

Group type: EXPERIMENTAL
Intervention: GP's personal letter with an evidence-based leaflet about overcoming barriers to accessing help for memory problems.
Number of subjects: 6378

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 6378
Study: 26124907

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg OD for 12 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg OD for 12 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg OD) + Atorvastatin (10 mg OD for 12 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (No treatment)
Number of subjects: 45
Study: 23872701

Group type: EXPERIMENTAL
Intervention: Intensive interoceptive exposure (IE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose interoceptive exposure (IE) as prescribed in Panic Control Treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose interoceptive exposure (IE) without controlled breathing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Expressive writing control
Number of subjects: 120
Study: 21291436

Group type: EXPERIMENTAL
Intervention: Parent‐Child Interaction Therapy (PCIT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 150
Study: 19843741

Group type: EXPERIMENTAL
Intervention: Oral contrast media
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: IV contrast media
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Oral and IV contrast media
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Simulated low radiation dose
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no contrast)
Number of subjects: 131
Study: 17402790

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bispecific antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VEGF or VEGF receptor blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat shock protein 90 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-targeted kinase inhibitors (sunitinib, sortenib)
Number of subjects: 0